SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

BioPharmX Corp. (BPMX)

BPMX RSS Feed
Add BPMX Price Alert      Hide Sticky   Hide Intro
Moderator: Whos_Who
Search This Board:
Last Post: 9/26/2016 9:57:09 AM - Followers: 11 - Board type: Free - Posts Today: 0

 

Biodelivery that makes a difference! 





We develop unique health and wellness products for licensing and commercialization in pharmaceutical and over-the-counter use.





 

   PRODUCTS

By design, BioPharmX's innovative drug delivery products, with their unique patented platform technologies, are formulated to address the needs of well-defined, fast-growing, multi-billion dollar markets, including dermatology, aesthetics, otolaryngology (ears, nose & throat), and women’s health.

BioPharmX currently has multiple products in various stages of development in all three of these markets, but its first commercialized product will be a woman’s breast health product launching in January 2015.

 

  Delivery Pathways

  BioPharmX creates unique drug delivery products for IP licensing or direct commercialization for pharmaceutical, over-the-counter, and supplement distribution and sales.




Product Types

Our unique health and wellness products (for licensing and commercialization in pharmaceutical and over-the-counter (OTC) use) leverage our extensive experience in pharmacological and biological sciences and drug delivery product development. Our team is experienced in performing pre-clinical studies focused on analytics, pharmacokinetics and toxicology, experimental design, and investigational protocols. We do this through product research and development and through strategic partnerships with leading worldwide pharmaceutical companies.

Our commitment to providing customers with products that improve the quality of their lives can only be met through unrivaled innovation and a dedication to quality—both of which are integral parts of BioPharmX's company culture.

 

   
            Over the Counter Products        

                    
 

With significant investments in R&D and a deep background in pharmaceutical and medical device development, BioPharmX is uniquely positioned to bring leading-edge, over-the-counter (OTC) products to the retail marketplace. Our products all meet rigorous internal quality measurements and leverage the capabilities required for pharmaceutical grade FDA products. 

                  

BioPharmX enables innovative solutions by working with pharmaceutical companies worldwide to achieve shorter time-to-market scenarios. We do this through a suite of core competencies unique to our teams:

♦ Customized solutions to fit drug formulation needs
♦ Expertise in regulatory, toxicology and clinical studies
♦ Streamlined pathways through development
♦ Unrivaled commitment to quality

 

 


 
 

  DEVELOPMENT RANGE

BioPharmX currently has multiple products in various stages of development for therapeutic drug delivery in the areas of women's health, dermatology, aesthetics and ENT.

 
 

 
 

  RESEARCH AND DEVELOPMENT

Our R&D team specializes in developing world-class clinical studies. They perform formulation development, outline safety profiles and dosing requirements, and set validation protocols. Currently they are developing a portfolio of patented drug applications (including novel formulations and minimally invasive delivery devices in respective markets) to be out-licensed or commercialized.

 

"Biopharmx's first product violet will hit market this fall"
"This company is a $$ maker." 
                                                

 

 
 

STRATEGIC PARTNERSHIPS

BioPharmX partners with leading pharmaceutical companies through regulatory approval or performs all activities internally, utilizing our team of regulatory and product development experts. Our partners turn to us to enhance delivery characteristics to improve drug performance and patient compliance. Our proven methods and technologies provide our customers with unique and measurable technical and competitive advantages.

 

 
 

Management Team

The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.


 



 

Jim Pekarsky                                                                                                                          
     
CHIEF EXECUTIVE OFFICER

Mr. Pekarsky has devoted over 30 years to growing diverse medical research and high-tech companies, including Bio Rad Laboratories, Mentor Graphics, MoSys and Virage Logic. He has spent over 10 years as the Chief Financial Officer of several public and private companies and five years as a European General Manager for U.S. multinational corporations. For more than a decade he has been counseling start-ups in Silicon Valley and leading their financings, acquisitions and initial public offerings. Pekarsky holds an M.B.A. in finance from Golden Gate University in San Francisco and a bachelor’s degree in accounting from Indiana University of Pennsylvania.

 

Anja Krammer                                                                                                                                    
       
PRESIDENT

A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.
 

Kin F. Chan, Ph.D.                                                                                                                             
     
EXECUTIVE VICE PRESIDENT OF RESEARCH AND TECHNOLOGY

Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, Chan was Vice President of Engineering at Demira, where he helped develop photodynamic therapies and directed advanced research at Solta Medical, where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.
 

Douglas Thomas, Ph.D.                                                                                                                     
      
CHIEF SCIENTIST

Dr. Thomas has more than 20 years of experience in biopharmaceutical research, process development, manufacturing and commercial development in start-ups and Fortune 500 companies. His background includes 10 years in business development and more than 10 years in research and development. He has consulted extensively in innovative start-ups focused on the application of diverse hardware and software in the biopharmaceutical industry. He has worked with a variety of biomedical companies, including BioSys Laboratories, Calypte Biomedical, Millipore and Invitrogen Life Technologies. Thomas holds a Ph.D. in immunology from Baylor College of Medicine and a bachelor’s degree in pharmacology from the University of California, Santa Barbara.
 

Jack Kessler, Ph.D.                                                                                                                           
       SCIENTIFIC ADVISOR

Dr. Kessler has more than 35 years of applied development experience in the area of iodine-based formulations, bio-analytical assays, in vitro diagnostic (IVD) medical devices and regulatory affairs. He is a named inventor on more than 20 U.S. patents for analytical assays, IVD medical devices, iodine-based disinfectants and formulations and pharmaceutical dosage forms. Kessler has also authored more than 20 publications and book chapters and participated on six federal research grants from the National Institute of Health and the U.S. Department of Agriculture. He received a doctorate in biochemistry from SUNY at Syracuse and a bachelor’s degree in chemistry from Stevens Institute of Technology in New Jersey.
 

AnnaMarie Daniels                                                                                                                             
       
SENIOR VICE PRESIDENT OF REGULATORY AND CLINICAL AFFAIRS

Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation and served as an independent consultant for a number of pharmaceutical and medical device companies.
 

Ross Portaro                                                                                                                                     
          SENIOR VICE PRESIDENT OF SALES

Mr. Portaro has 30 years of global sales executive experience in dermatology, women's health, and aesthetics. In dermatology, most recently as a sales director at Ulthera, he doubled sales and positioned them for their 2014 acquisition by Merz. At Medicis, Portaro led the LipoSonix team in Europe and facilitated the sale to Solta in 2011. In Women's Health, he built the original sales team at SenoRx, which was the leader in breast biopsies devices and had a successful 2007 IPO. In aesthetics, Mr. Portaro started TRIA Beauty as the Vice President of Sales and was the first medical laser executive to globally launch a medical-grade laser for hair removal into the consumer OTC Market. TRIA Beauty is positioned for a 2014 IPO. Mr. Portaro received his BS in Commerce from the McIntyre School of Commerce at the University of Virginia.
 
Stephen Morlock                                                                                                                                    
          DIRECTOR
A seasoned financial executive and retail industry veteran, has been added to its board of directors.  Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.

Morlock previously served as executive vice president and chief financial officer from 1994 to 2004 at Otis Spunkmeyer, a baked goods distribution company that has successfully pursued distribution of its products to small family-owned businesses all the way up to large worldwide organizations, including the U.S. Army.  He served as controller there from 1992 to 1994.  He also has experience garnered from these roles in various aspects of the retail industry, including going to market via various distribution channels, product merchandizing, customer relationship management, brand development, manufacturing, procurement, and inventory management.   

"Stephen brings a unique blend of financial expertise and experience in the retail industry to BioPharmX," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX Corporation.  "His expertise and experience will prove valuable as we continue retail distribution expansion for Violet iodine."

Prior to his roles at Otis Spunkmeyer, Morlock held various management positions in accounting, financial planning and internal auditing at Westinghouse Electric Supply Company from 1977 to 1991. He holds a B.S. degree in Accounting from San Diego State University



 

Corporate Headquarters

BioPharmX, Inc.
1098 Hamilton Court
Menlo Park, CA 94025
650.889.5020


SEC Filings link below.
http://yahoo.brand.edgar-online.com/default.aspx?cik=1504167



OneMed San Francisco 2014 Webcast http://www.onemedplace.com/onemedtv/play.php?vid=2570
 
BPMX

2015 Second Quater Finacial Results Webcast http://78449.choruscall.com/dataconf/productusers/bpmx/media/bpmx150914a.mp3

 

            

 

 




 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BPMX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
News News Alert: Securities Registration Statement (simplified Form) (s-3/a) 09/26/2016 04:06:16 PM
PostSubject
#225  Sticky Note BioPharmX BPMX Corporate Presentation Whos_Who 05/20/16 04:54:52 PM
#293   BioPharmX Announces Registered Direct Offering Whos_Who 09/26/16 09:57:09 AM
#292   BioPharmX Announces Registered Direct Offering Whos_Who 09/26/16 09:57:01 AM
#291   BioPharmX Announces Registered Direct Offering Whos_Who 09/26/16 09:56:54 AM
#290   Thanks!. May be time to load the truck. docoroc2 09/20/16 08:44:01 AM
#289   On September 15, 2016, BioPharmX Corporation (“Company”) received Whos_Who 09/19/16 06:18:13 PM
#288   RESEARCH REPORT UPDATE Whos_Who 09/16/16 12:58:44 PM
#287   Second Quarter Financial Results Whos_Who 09/12/16 10:14:11 PM
#286   You are correct: 0.56%, according to a recent docoroc2 09/07/16 03:15:11 PM
#285   Anyone has any idea what caused the volume pennyroller16 09/06/16 12:15:24 PM
#284   BioPharmX to Report Second Quarter Financial Results Whos_Who 09/02/16 08:04:37 AM
#283   They show it on the Pink-sheets site, even docoroc2 09/01/16 11:19:12 AM
#282   Can you provide any info to your research Whos_Who 08/31/16 09:34:55 PM
#281   Thanks for that. Has the company proposed remedies docoroc2 08/31/16 10:48:44 AM
#280   Good article here... Whos_Who 08/26/16 01:20:00 PM
#279   Any news on the possible de-listing and the docoroc2 08/24/16 11:25:03 AM
#278   Yes, I read this. Interestingly, the trial will docoroc2 08/24/16 09:55:46 AM
#277   BioPharmX Enrolls First Subject in OPAL Phase 2b Whos_Who 08/24/16 08:03:52 AM
#276   nice IN The Mouth Of Madness 08/24/16 01:20:54 AM
#275   BioPharmX Announces Final Phase 2a Trial Results Find Whos_Who 08/22/16 10:01:29 AM
#274   Do your DD. Looks like purchase agreements floating Whos_Who 08/19/16 08:14:05 AM
#273   Nice above average volume again!. We need to Whos_Who 08/17/16 06:16:20 PM
#272   More insider buying action lately! Whos_Who 08/16/16 07:57:45 PM
#271   Oh yeah! I believe there's good and plentiful Whos_Who 08/15/16 09:39:49 PM
#270   Great volume. The .80s can't be far off. jnl57 08/15/16 03:20:55 PM
#269   There should be an update any day concerning jnl57 08/15/16 11:50:08 AM
#268   I'm loading the boat in the mid .60's. jnl57 08/13/16 09:35:35 AM
#267   BPMX bullish 0.70 stocktrademan 08/04/16 11:23:41 AM
#266   bulls running more Chance 07/27/16 07:22:55 AM
#265   Agreed I see the same! Break $.80 and TheProfit 07/24/16 08:14:13 PM
#264   Chart is showing a fight to break resistance Whos_Who 07/23/16 02:43:21 PM
#263   Look at post 253 that I made last jnl57 07/23/16 11:30:27 AM
#262   Biotech Breakouts Now for Big Gains Whos_Who 07/22/16 09:21:57 PM
#261   Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Whos_Who 07/22/16 09:04:30 PM
#260   I could not agree more. I'm hoping it's jnl57 07/22/16 11:21:25 AM
#259   Very interesting volume the past few days. Something Whos_Who 07/22/16 11:15:44 AM
#258   I think it would be a very bullish jnl57 07/22/16 11:13:43 AM
#257   Keeping an Eye on Unusual Volume for BioPharmX Whos_Who 07/21/16 08:30:02 AM
#256   BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Whos_Who 07/21/16 08:06:00 AM
#255   SRC / ZACKS RESEARCH REPORT UPDATE Whos_Who 07/13/16 11:54:19 PM
#254   Sabby Management LLC acquired a new stake in Whos_Who 07/08/16 08:00:59 AM
#253   BiopharmX should be worth .90 - $1 (at jnl57 07/03/16 12:12:40 PM
#252   As Biopharmx prepares to launch Phase 2b study Whos_Who 07/01/16 08:05:30 AM
#251   In my opinion, I believe your doing the Whos_Who 06/30/16 03:21:30 PM
#250   Adding 5000 more @ 0,63$ this morning. THEBELGIAN77 06/30/16 11:48:50 AM
#249   More To Come Whos_Who 06/29/16 08:40:02 AM
#248   Positive Topline Phase 2a Clinical Trial Results for Whos_Who 06/29/16 08:34:20 AM
#247   Huge News! Premarket up! Whos_Who 06/29/16 08:30:19 AM
#246   BioPharmX Announces Positive Topline Phase 2a Clinical Trial Whos_Who 06/29/16 08:13:40 AM
#245   I'm continuing to hold BPMX mainly because Franklin jnl57 06/19/16 11:39:37 AM
#244   It sure would be nice to get some jnl57 06/17/16 09:57:28 AM
PostSubject